Glucagen Hypokit (Glucagon)

Glucagen Hypokit is indicated for the rapid reversal of severe hypoglycemia, particularly when a patient cannot safely consume oral carbohydrates.

• Treatment of insulin‑induced hypoglycemia that results in loss of consciousness or seizures.
• Emergency management of hypoglycemia in patients with type 1 or type 2 diabetes.
• Use in hospital or pre‑hospital settings when intravenous dextrose is unavailable.
• Administration by trained caregivers or medical personnel during a hypoglycemic crisis.
• Adjunct therapy for patients on high‑dose insulin regimens who are at risk of sudden glucose drops.

The safety profile of Glucagen Hypokit reflects the pharmacologic actions of glucagon and the injection route.

Common

• Nausea or vomiting.
• Headache.
• Flushing or warmth sensation.
• Injection‑site pain, redness, or swelling.
• Transient dizziness.

Serious

• Allergic reactions such as rash, itching, or anaphylaxis.
• Severe hyperglycemia requiring medical attention.
• Electrolyte disturbances, including hypokalemia.

Before using Glucagen Hypokit, certain precautions should be considered to ensure safe and effective treatment.

• Contraindicated in patients with pheochromocytoma, insulinoma, or adrenal insufficiency.
• Do not use if the patient has a known hypersensitivity to glucagon or any excipients.
• Monitor blood glucose levels after administration to confirm response.
• Ensure the kit is intact; discard if the container is damaged or the solution is discolored.
• Follow proper reconstitution and injection technique as described in the prescribing information.
• Store according to label instructions, protecting from extreme temperatures.
• Use pediatric dosing guidelines when treating children, if applicable.

Glucagon can interact with other medications, affecting its efficacy or safety.

Avoid

• Concomitant use of high‑dose insulin that may mask the glucose‑raising effect of glucagon.
• Beta‑adrenergic antagonists that could blunt the physiological response to glucagon.

Use with caution

• Beta‑adrenergic agonists (e.g., albuterol) as they may enhance hyperglycemic effects.
• Oral contraceptives or hormone therapy, which can alter glucose metabolism.
• Catecholamines or sympathomimetic agents, which may increase the risk of severe hyperglycemia.
• Calcium channel blockers, which may affect cardiovascular response to glucagon.